is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://dev.cherrycoding.com/mergerscorp/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
描述
这家制药公司于约 40 年前在约旦安曼成立。 它拥有 70 多项专利，是地区创新标杆。
这种创新的直接结果是，通过将成熟的技术平台分拆成拥有独立管理和资源的子公司，在传统的非专利药品行业之外实现了业务多元化。
纵向
1.核心品牌非专利药品业务。
2.通过子公司获得天然产品。
3.通过子公司开展生物技术诊断。
4.通过子公司开发新型辅料和给药系统。
产品
产品涵盖广泛的治疗类别，包括心血管、胃肠道、中枢神经系统、抗感染、内分泌、肌肉骨骼、呼吸系统、妇产科和泌尿系统以及免疫系统。
制药业务
它提供 200 多种药品，满足消费者和医疗保健专业人员的需求。 这些产品包括片剂、胶囊、栓剂、糖浆和混悬液，均按照《药品生产质量管理规范》（GMP）生产。 由于产品 “质量 “高，该公司具有竞争优势，成为领先的制药公司之一。
天然产品
该公司在中东地区享有盛誉，是利用标准化药用植物提取物开发和生产植物和草药医疗产品的最佳企业之一，提供 50 多种天然和草药创新产品，业务遍及全球 20 多个国家。
生物技术
它是一家专有生物技术保健产品的开发商和生产商，专门从事生产。
Basic Details
Target Price:
$ 45,000,000
Gross Revenue
$37,000,000
EBITDA
$6,279,944
Business ID:
L#20230509
Country
约旦
详情
Published on 21 8 月, 2023 在 11:59 上午. 更新 26 8 月, 2025 在 8:53 上午